NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/03/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization47.29 mln
Float31.95 mln
Earnings Date08/12/2026
Relative Strength
16
/ 100
Significantly lagging
Debt / Equity
-0.01
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Payout Ratio
0%
No payout
ROA
-26.91
Deeply negative
Business Description
BeyondSpring Inc. is a New Jersey-based biopharmaceutical company focused on developing new treatments for cancer. Its most advanced drug, Plinabulin, has completed Phase III clinical trials and is being studied both as a cancer-fighting agent and as a way to reduce a common side effect of chemotherapy known as low white blood cell count. The company is also testing Plinabulin alongside other established cancer drugs and exploring a separate pipeline of early-stage molecules through its drug discovery platform. Founded in 2010, BeyondSpring continues to expand its research across multiple cancer types and treatment approaches.
